Cargando…

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach

BACKGROUND: Long-acting injectable antipsychotics (LAIs) are an essential maintenance treatment option for individuals with schizophrenia or bipolar I disorder (BP-I). This report summarizes a roundtable discussion on the impact of COVID-19 on the mental healthcare landscape and use of LAIs for indi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Correll, Christoph U., Chepke, Craig, Gionfriddo, Paul, Parks, Joe, Foxworth, Phyllis, Basu, Anirban, Brister, Teri S., Brown, Dawn, Clarke, Christopher, Hassoun, Youssef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745550/ https://www.ncbi.nlm.nih.gov/pubmed/35012512 http://dx.doi.org/10.1186/s12888-022-03685-w

Ejemplares similares

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic, Martha, et al.
Publicado: (2018)

Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
por: Yavuz, E., et al.
Publicado: (2022)

Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
por: Yavuz, E., et al.
Publicado: (2023)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection
por: Samalin, L, et al.
Publicado: (2010)

A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder
por: Chou, Yuan Hwa, et al.
Publicado: (2015)

The effect of long-acting injectable antipsychotics on QRISK3 in patients with bipolar disorder and schizophrenia
por: Erbasan, V., et al.
Publicado: (2023)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

PM379. Quality of Life in patients with schizophrenia or bipolar disorder receiving long-acting antipsychotics
por: Lin, Shih-Ku
Publicado: (2016)

Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis
por: Prajapati, Asta R., et al.
Publicado: (2018)

Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies
por: Bartoli, Francesco, et al.
Publicado: (2023)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review
por: CORRELL, Christoph U., et al.
Publicado: (2016)

Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
por: Bossie, Cynthia A., et al.
Publicado: (2015)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

The use of atypical antipsychotics in Bipolar Spectrum disorders
por: Grünze, H., et al.
Publicado: (2003)

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
por: Coles, Alexandria S., et al.
Publicado: (2021)

Clinical predictors of therapeutic response to antipsychotics in schizophrenia
por: Carbon, Maren, et al.
Publicado: (2014)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
por: Litman, Robert, et al.
Publicado: (2023)

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
por: Sajatovic, Martha, et al.
Publicado: (2018)

Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients
por: Torrent, Carla, et al.
Publicado: (2010)

Antipsychotic Effects on Cortical Morphology in Schizophrenia and Bipolar Disorders
por: Feng, Ruiqi, et al.
Publicado: (2020)

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics
por: Kheloussi, Steven, et al.
Publicado: (2022)

T236. A PROGRAM TO INCREASE THE APPROPRIATE USE OF LONG-ACTING ANTIPSYCHOTIC MEDICATIONS IN COMMUNITY SETTINGS
por: Velligan, Dawn, et al.
Publicado: (2020)

Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2016)

Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study
por: Basu, Anirban, et al.
Publicado: (2022)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Atypical antipsychotics in bipolar disorder: systematic review of randomised trials
por: Derry, Sheena, et al.
Publicado: (2007)

Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia
por: Yu, Chia-Ling, et al.
Publicado: (2023)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey
por: Bessonova, Leona, et al.
Publicado: (2020)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry
por: Stip, Emmanuel, et al.
Publicado: (2020)

The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder
por: Mundo, Emanuela, et al.
Publicado: (2006)

Borderline Personality Disorder: Bipolarity, Mood Stabilizers and Atypical Antipsychotics in Treatment
por: Belli, Hasan, et al.
Publicado: (2012)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy
por: Jauhar, Sameer, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hjkd6b6bfrj872o8i26msdqb6k